🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fribourg
Clinical trial register · Switzerland

Clinical Trials in Fribourg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Switzerland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2252 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:47 UTC
2252
Studies in scope
all four open statuses
1374
Recruiting now
open to new participants
530
Lead sponsors
across recruiting studies
Top sites
Zurich 738 Bern 720 Basel 635 Geneva 402 Lausanne 394
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Swiss Cancer Institute8 Insel Gruppe AG, University Hospital Bern4 Stichting Hemato-Oncologie voor Volwassenen Nederland4 University of Fribourg3 Merck Sharp & Dohme LLC3
Site location
Zurich738 Bern720 Basel635 Geneva402 Lausanne394
All 149 locations
Target enrolment
to

Trials with a site in Fribourg

70 of 2252 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Switzerland
Start
Not yet open
Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee
NCT05651997Articular Cartilage Defect, Chondral Defect, Osteochondritis
Centre Hospitalier Universitaire Vaudois
Not applicable
80
Fribourg, Lausanne
2026-12
Not yet open
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
NCT07574047Melanoma, Advanced Melanoma
Swiss Cancer Institute
Phase 2
108
Fribourg, Bellinzona, Bern, Geneva, Lausanne, Münsterlingen, Sankt Gallen, Zurich
2026-09
Recruiting
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
NCT07158489NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsIvonescimab·Gemcitabine
Swiss Cancer Institute
Phase 2
47
Baden, Basel, Bellinzona, Chur, Fribourg, Geneva, Winterthur
2026-08-21
Recruiting
Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
NCT06653738Kidney Stone, Nephrolithiasis, Dietary Exposure
DrugDapagliflozin
Insel Gruppe AG, University Hospital Bern
Phase 3
400
Aarau, Baden, Basel, Bern, Chur, Fribourg, Geneva, Lausanne
2026-07-02
Not yet open
Investigating the Neurophysiology of the Motor System and the Feasibility of Vagus Nerve Stimulation in Functional Neurological Disorder (FND)
NCT07710677Functional Neurological Disorder, Motor Symptoms
University of Fribourg
Not applicable
68
Fribourg
2026-07-01
Not yet open
Assessing and Improving Misuse of Inhalers in COPD Outpatients
NCT07264140Chronic Obstructive Pulmonary Disease (COPD)
Hôpital Fribourgeois
Not applicable
116
Fribourg
2026-06-01
Recruiting
Giving Children a Voice in Paediatric Anaesthesia
NCT07524049Perioperative Care, Pediatric Anesthesia, Pain Management, Anxiety
Insel Gruppe AG, University Hospital Bern
Observational
1,040
Aarau, Basel, Bern, Fribourg, Geneva, Lucerne, Bellinzona
2026-05-27
Recruiting
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
NCT07203053Extensive Stage Lung Small Cell Cancer
DrugTarlatamab
ETOP IBCSG Partners Foundation
Phase 2
48
Baden, Fribourg, Geneva, Sankt Gallen
2026-04-15
Recruiting
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
NCT07020065Metastatic NSCLC - Non-Small Cell Lung Cancer
DrugsCemiplimab·Paclitaxel·Carboplatin
Swiss Cancer Institute
Phase 2
156
Fribourg, Aarau, Baden, Basel, Bern, Bruderholz, Chur, Frauenfeld
2026-04-10
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814Acute Myeloid Leukemia
DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
875
Bern, Fribourg, Geneva, Sankt Gallen, Zurich
2026-03-01
Active, closed
ELUDYN: Assessment of Intra-individual Variability of Vascular Dynamics of Gadopiclenol Injection Parameters in Contrast-enhanced MRI
NCT07346131Contrast Agent, Medical Imaging Data, MRI Image Enhancement
Hôpital Fribourgeois
Phase 4
14
Fribourg
2026-01-07
Recruiting
Influence of Tea Extract on Maximal Voluntary Knee Contraction Following Downhill Jogging
NCT07113405Muscle Recovery
University of Fribourg
Not applicable
60
Fribourg
2025-12-01
Recruiting
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
NCT07263438Glioblastoma, Recurrence Tumor
DrugsAtezolizumab·Bevacizumab
Centre Hospitalier Universitaire Vaudois
Phase 2
59
Basel, Aarau, Bern, Fribourg, Lucerne, Lausanne, Zurich
2025-11-03
Recruiting
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
DrugsPemetrexed /m^2·Visugromab·Carboplatin·Pembrolizumab
CatalYm GmbH
Phase 2
107
Basel, Fribourg, Sankt Gallen
2025-08-01
Recruiting
The COMET Study: a Prospective COhort of MEdical residenTs to Assess Professional, Personal and Psychological Trajectories of Residents in General Internal Medicine
NCT07707453Burnout Syndrome, Depression Disorder, Insomnia, Perceived Stress
University of Fribourg
Observational
800
Bern, Fribourg, Lausanne
2025-08-01
Active, closed
Polygenic Risk Score for Optimizing Primary Prevention in Intermediate-Risk Populations
NCT07039123Primary Prevention of Cardiovascular Disease
University of Bern
Not applicable
205
Bern, Fribourg
2025-07-08
Not yet open
FOllow-up of LOW-acuity Patients After REdirection From a Swiss Emergency Department Using an Electronic TRIage Application
NCT06971419Triage, Low Acuity Patients, Health Literacy Level, Non-urgent Emergencies
Hôpital Fribourgeois
Observational
450
Fribourg
2025-06-15
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Aarau, Basel, Geneva, Fribourg, Zurich
2025-05-13
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Basel, Fribourg, Sankt Gallen
2025-05-06
Recruiting
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
NCT06466382Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Ovarian Endometrioid Carcinoma, High-grade Serous Ovarian Carcinoma (HGSOC)
Swiss GO Trial Group
Not applicable
60
Baden, Basel, Sankt Gallen, Frauenfeld, Bern, Fribourg, Zurich
2025-03-31
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Baden, Fribourg, Locarno
2025-03-27
Not yet open
NapBiome: Targeting Gut Microbiota and Sleep Rhythm to Improve Developmental and Behavioral Outcomes in Early Childhood
NCT06396689Sleep Problem, Neurobehavioral Manifestations
Petra Zimmermann
Not applicable
380
Fribourg, Lucerne
2025-03-01
Recruiting
A Trial of Placebo Versus Macrolide for Mycoplasma Pneumoniae Childhood Pneumonia: MYTHIC Study
NCT06325293Community Acquired Pneumonia in Children, Mycoplasma Pneumoniae, Mycoplasma Pneumoniae Pneumonia
Christoph Berger
Not applicable
376
Aarau, Basel, Bern, Fribourg, Geneva, Lucerne, Sankt Gallen, Lausanne
2025-01-28
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Fribourg, Geneva, Lausanne
2025-01-28
Recruiting
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
NCT06284317Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation
Phase 3
290
Baden, Basel, Bellinzona, Bern, Fribourg, Lausanne, Sankt Gallen, Winterthur
2025-01-15
Recruiting
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
NCT06465498Acute Heart Failure
Antonio Leidi
Not applicable
222
Geneva, Bern, Fribourg, Lugano
2024-10-22
Recruiting
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306Extensive Stage Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 1
220
Chur, Fribourg, Winterthur
2024-10-07
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
Baden, Fribourg
2024-08-28
Recruiting
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301Metastatic Non-small Cell Lung Cancer
DrugPembrolizumab
NovoCure GmbH
Phase 3
734
Baden, Fribourg
2024-07-31
Recruiting
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
NCT05373264ADPKD
DrugHydrochlorothiazide
University Medical Center Groningen
Phase 3
300
Bern, Fribourg, Geneva, Zurich
2024-07-31
Active, closed
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261Leukemia, Myeloid, Acute
DrugsCusatuzumab·Azacitidine·Venetoclax
OncoVerity, Inc.
Phase 2
140
Bern, Fribourg, Sankt Gallen
2024-07-22
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
DrugsSacituzumab tirumotecan·Capecitabine·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,530
Thun, Geneva, Zurich, Chur, Fribourg
2024-06-24
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Lausanne, Chur, Münsterlingen, Fribourg
2024-04-03
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Basel, Fribourg, Geneva, Lausanne, Zurich
2024-03-21
Active, closed
LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma
NCT06090162Non-hodgkin Lymphoma, B Cell
Swiss Cancer Institute
Not applicable
64
Aarau, Basel, Bellinzona, Bern, Chur, Fribourg, Geneva, Lausanne
2024-03-12
Recruiting
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
NCT06556446Ischemic Stroke
Insel Gruppe AG, University Hospital Bern
Observational
2,800
Aarau, Basel, Bern, Fribourg, Geneva, Lausanne, Lucerne, Lugano
2024-01-01
Recruiting
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
NCT06114108Non-small Cell Lung Cancer (NSCLC), Stage IV
Swiss Cancer Institute
Not applicable
128
Aarau, Bellinzona, Chur, Fribourg, Geneva, Lucerne, Zurich
2023-12-21
Recruiting
Efficacy of Lavender Essential Oil Chest Wraps in Infants With Bronchiolitis
NCT06108648Bronchiolitis
University Hospital, Geneva
Phase 4
400
Fribourg, Geneva
2023-12-07
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Ipilimumab·Pemetrexed·Nivolumab
AstraZeneca
Phase 3
863
Baden, Basel, Bern, Fribourg, Sankt Gallen
2023-11-09
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,295
Baden, Frauenfeld, Fribourg, Geneva, La Chaux-de-Fonds, Lausanne, Liestal, Sankt Gallen
2023-10-24
Recruiting
eUltra 10k - Biofreedom Ultra
NCT05505929Post Market Clinical Follow up (PMCF)
Biosensors Europe SA
Observational
10,000
Fribourg, Zurich
2023-06-15
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Chur, Fribourg, Geneva, Sankt Gallen, Winterthur
2023-05-31
Recruiting
Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence
NCT05266807Clostridioides Difficile Infection
DrugsFidaxomicin·Vancomycin
Benoit Guery
Phase 3
100
Basel, Bern, Fribourg, Lucerne, Sankt Gallen, Lausanne, Zurich, Sion
2023-03-15
Recruiting
Swiss Revision Cohort
NCT07473089Joint (Knee or Hip Replacement), Infection as Complication of Medical Care
Insel Gruppe AG, University Hospital Bern
Observational
329
Aarau, Bern, Fribourg, Geneva, Lausanne
2022-09-23
Active, closed
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
NCT05399992Primary Hypercholesterolemia, Mixed Dyslipidemia
Novartis Pharmaceuticals
Observational
847
Fribourg, Basel, Geneva, Lausanne, Olten, Sankt Gallen, Zurich
2022-09-12
Recruiting
Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland
NCT05819463Atopic Dermatitis
Swiss Society of Dermatology and Venereology
Observational
700
Basel, Bern, Buochs, Fribourg, Lausanne, Lucerne, Sankt Gallen, Uster
2022-06-02
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
DrugsZanubrutinib·Obinutuzumab·Lenalidomide·Rituximab
BeOne Medicines
Phase 3
799
Fribourg, La ChauxdeFonds, Zurich
2022-03-10
Active, closed
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
NCT05063786Advanced Breast Cancer
DrugsAlpelisib·Herceptin·Xeloda·Vinorelbine
Spanish Breast Cancer Research Group
Phase 3
27
Aarau, Bern, Fribourg
2021-09-14
Active, closed
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
NCT05049798Arthritis, Psoriatic
DrugsIL-17i·Guselkumab
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Fribourg
2021-08-25
Active, closed
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
NCT04604067Diffuse Large B-cell Lymphoma
DrugAcalabrutinib
Swiss Cancer Institute
Phase 2
260
Aarau, Baden, Basel, Bellinzona, Bern, Chur, Fribourg, Geneva
2021-06-25
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Basel, Bern, Fribourg, Geneva, Sankt Gallen, Zurich
2021-05-15
Recruiting
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
NCT04774159Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
DrugColchicine
Population Health Research Institute
Phase 3
6,150
Basel, Bellinzona, Fribourg, Geneva, Zurich
2021-05-06
Active, closed
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318Chronic Lymphoid Leukemia
DrugsIbrutinib·Obinutuzumab·Venetoclax
German CLL Study Group
Phase 3
897
Aarau, Baden, Basel, Bellinzona, Bern, Brig, Chur, Fribourg
2021-03-01
Active, closed
Major Adverse Limb Events in Patients With Femoro-popliteal and Below-the-knee Peripheral Arterial Disease Treated With Either Sirolimus-coated Balloon or Standard Uncoated Balloon Angioplasty
NCT04238546Peripheral Arterial Disease
Nils Kucher
Not applicable
1,200
Zurich, Fribourg
2020-11-03
Recruiting
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT04263038Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases
DrugRivaroxaban
Drahomir Aujesky
Phase 4
276
Liestal, Aarau, Bern, Biel/Bienne, Fribourg, Lucerne, Olten, Sankt Gallen
2020-05-15
Active, closed
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
DrugsMidostaurin·Gilteritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
777
Aarau, Basel, Bellinzona, Bern, Fribourg, Geneva, Lausanne, Lucerne
2019-12-20
Active, closed
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
NCT04097470AML/MDS
DrugsMidostaurin·Decitabine
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2
140
Aarau, Basel, Bellinzona, Bern, Fribourg, Geneva, Lausanne, Lucerne
2019-12-05
Active, closed
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
NCT03820830Breast Cancer Recurrent
DrugPalbociclib
ETOP IBCSG Partners Foundation
Phase 3
405
Baden, Basel, Bern, Fribourg, Locarno, Lucerne, Winterthur, Zurich
2019-08-27
Active, closed
Enhancement of Stroke Rehabilitation With Levodopa
NCT03735901Acute Stroke, Stroke Rehabilitation
University Hospital, Basel, Switzerland
Phase 3
610
Aarau, Bad Zurzach, Baden, Basel, Bern, Chur, Fribourg, Lausanne
2019-06-14
Active, closed
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
DrugsEnasidenib·Ivosidenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
968
Basel, Bellinzona, Bern, Fribourg, Geneva, Lucerne, Sankt Gallen, Zurich
2019-03-01
Recruiting
PTX3-targeted Antifungal Prophylaxis
NCT03828773Candidiasis, Fungal Infection, Acute Myeloid Leukemia, Genetic Predisposition
DrugsFluconazole·Posaconazole
Bochud Pierre-Yves
Not applicable
410
Aarau, Basel, Fribourg, Geneva, Lausanne
2019-02-11
Active, closed
1st Line Durvalumab in PS 2 NSCLC Patients
NCT03620669NSCLC Stage IV, NSCLC Stage IIIB
DrugDurvalumab
Swiss Cancer Institute
Phase 2
48
Aarau, Baden, Basel, Bellinzona, Bern, Chur, Fribourg, Geneva
2018-12-04
Recruiting
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
NCT03124212Hereditary Breast and Ovarian Cancer, Lynch Syndrome
University of Basel
Observational
700
Fribourg, Geneva, Delémont, Winterthur, Basel, Bellinzona, Bern
2017-04-01
Active, closed
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
NCT02710435Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
Shockwave Medical, Inc.
Observational
400
Basel, Fribourg, Geneva, Lugano
2016-03
Active, closed
PALbociclib CoLlaborative Adjuvant Study
NCT02513394Breast Cancer
DrugPalbociclib
Alliance Foundation Trials, LLC.
Phase 3
5,796
Baden, Thun, Geneva, Bellinzona, Locarno, Chur, Basel, Fribourg
2015-08
Active, closed
Micra Transcatheter Pacing System Post-Approval Registry
NCT02536118Bradycardia
Medtronic
Observational
3,100
Basel, Bern, Fribourg, Geneva, Lausanne, Lugano, Zurich
2015-07
Recruiting
Percutaneous Coronary Intervention Registry FRIBOURG
NCT04185285Coronary Artery Disease, Percutaneous Coronary Intervention
University of Freiburg
Observational
3,000
Fribourg
2015-05-01
Active, closed
Prostate Cancer Biobank
NCT04024475Prostatic Neoplasms
Swiss Cancer Institute
Observational
1,323
Baden, Basel, Bern, Biel, Chur, Fribourg, Geneva, Lucerne
2014-11-04
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Basel, Bern, Fribourg, Geneva, Lausanne, Lugano, Meyrin, Morges
2012-01
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Medtronic
Observational
20,000
Basel, Bern, Fribourg, Geneva, Lausanne, Lugano, Zurich
1983-01
Rows per page Showing 1–70 of 70
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Swiss investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-switzerland/city/fribourg

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Switzerland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,252 studies in total at the last sync on 26 Sep 2026, 19:47 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 70 of those studies with a site in Fribourg.

How many clinical trials are recruiting in Fribourg?

40 of the 70 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:47 UTC sync. A further 6 have not yet opened recruitment, 24 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fribourg), 70 studies
PhaseStudiesRecruitingShare
Phase 3241434.3%
Observational171124.3%
Not applicable14620%
Phase 210514.3%
Phase 4324.3%
Phase 1111.4%
Phase 2/3111.4%

Most active sponsors

Lead sponsors with the most studies (Fribourg)
Lead sponsorStudiesRecruiting
Swiss Cancer Institute83
Insel Gruppe AG, University Hospital Bern44
Stichting Hemato-Oncologie voor Volwassenen Nederland41
ETOP IBCSG Partners Foundation32
Hôpital Fribourgeois30
Medtronic32
Merck Sharp & Dohme LLC33
University of Fribourg32
Amgen21
Centre Hospitalier Universitaire Vaudois21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.